Nebivolol versus nifedipine in the treatment of essential hypertension: A double-blind, randomized, comparative trial

American Journal of Therapeutics

Volumn 5, Issue 4, 1998, Pages 237-243

  Van Nueten, L ^a   Lacourciere Y ^b   Vyssoulis, G ^c   Korlipara, K ^d   Marcadet, D M ^e   Dupont, A G ^a   Robertson, J I S ^a  

^a JANSSEN RESEARCH FOUNDATION   (Belgium)

^b LAVAL UNIVERSITY   (Canada)

^c Ippokrateion   (Greece)

^d Pike View Medical Centre ^*  (United Kingdom)

^e Service Parisien de Santé Environnementale   (France)

Author keywords

Ambulatory blood pressure; Calcium antagonist; Drug side effects; L arginine; Nitric oxide; Plasma lipids; blocker

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; NEBIVOLOL; NIFEDIPINE; VASODILATOR AGENT;

ADULT; AGED; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SCREENING; EDEMA; ESSENTIAL HYPERTENSION; FATIGUE; FEMALE; HEADACHE; HEART PALPITATION; HUMAN; IMPOTENCE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PARESTHESIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; VERTIGO;

EID: 0031876214     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/00045391-199807000-00006     Document Type: Article

References (25)

1. Fitzgerald JD (ed): First International Nebivolol Investigators' Meeting. Drug Invest 1991;3(Suppl 1):1-203.
2. 1-adrenergic antagonist. J Cardiovasc Pharmacol 1988;11:552-563.
3. Pauwels PJ, Gommeren W, Van Lommen G, et al: The receptor binding profile of the new antihypertensive agent nebivolol and its stereoisomers compared with various beta-1 adrenergic blockers. Mol Pharmacol 1988; 34:843-851.
4. Janssens WJ, Van den Water A, Xhonneux R, et al: Nebivolol is devoid of intrinsic sympathomimetic activity. Eur J Pharmacol 1989;159:89-95.
5. Van de Water A, Xhonneux R, Reneman RS, et al: Cardiovascular effects of DL-nebivolol and its enantiomers: a comparison with those of atenolol. Eur J Pharmacol 1988;156:95-103.
6. Gao Y, Nagao T, Bond RA, et al: Nebivolol induces endothelium-dependent relaxations of canine coronary arteries. J Cardiovasc Pharmacol 1991;17:964-969.
7. Cockroft JR, Chowienczyk PJ, Brett SA, et al: Nebivolol vasodilates human forearm vasculature: evidence for an L-arginine/NO-dependent mechanism. J Pharmacol Exp Ther 1995;274:1067-1071.
8. Bowman AJ, Chen CPL-H, Ford GA: Nitric oxide mediated venodilator effects of nebivolol. Br J Clin Pharmacol 1994;38:199-204.
9. Van Rooy P, Van Nueten L, De Crée J: Nebivolol blood pressure reduction in relation to beta-blockade in healthy volunteers. Drug Invest 1991;3(Suppl 1):174-175.
10. Lacourcière Y, Poirier L, Lefebvre J, et al: Treatment of ambulatory hypertensives with nebivolol or hydrochlorothiazide alone and in combination. A randomized, double-blind, placebo-controlled, factorial-design trial. Am J Hypertens 1994;7:137-145.
11. Van Bortel LM, Breed JG, Joosten J, et al: Nebivolol in hypertension: a double-blind placebo-controlled multicentre study assessing its antihypertensive efficacy and impact on quality of life. J Cardiovasc Pharmacol 1993; 21:856-862.
12. Van Nueten L, Dupont AG, Vertommen C, et al: A dose-response trial of nebivolol in essential hypertension. J Hum Hypertens 1997;11:139-144.
13. Stoleru L, Wijns W, Van Eyll C, et al: Effects of D-nebivolol and L-nebivolol on the left ventricular systolic and diastolic function: comparison with DL-nebivolol and atenolol. J Cardiovasc Pharmacol 1993;22:183-190.
14. Goldstein M, Vincent JL, De Smet JM, et al: Administration of nebivolol after coronary artery bypass graft in patients with altered left ventricular function. J Cardiovasc Pharmacol 1993;22:253-258.
15. Wisenbaugh T, Katz I, Davis J, et al: Long-term (3 month) effects of a new beta-blocker (nebivolol) on cardiac performance in dilated cardiomyopathy. J Am Coll Cardiol 1993;21:1094-1100.
16. Uhlir O, Dvorak J, Gregor P, et al: Nebivolol in the treatment of cardiac failure: a double-blind controlled clinical trial. J Card Fail (in press).
17. Rousseau MF, Chapelle F, Van Eyll C, et al: Medium term effects of beta-blockade on left ventricular mechanics: a double-blind, placebo controlled comparison of nebivolol and atenolol in patients with ischemic left ventricular dysfunction. J Card Fail 1996;2:15-23.
18. Lacourcière Y, Poirier L, Lefebvre J, et al: Comparative effects of a new cardioselective beta-blocker nebivolol and nifedipine sustained-release on 24-hour ambulatory blood pressure and plasma lipoproteins. J Clin Pharmacol 1992;32:660-666.
19. Lipicky RJ: Trough:peak ratio: the rationale behind the United States Food and Drug Administration recommendations. J Hypertens 1994;12(Suppl 8):17-19.
20. Dollery CT, Boobis AR, Burley D, et al (eds): Therapeutic Drugs, 2nd vol. Churchill Livingstone, Edinburgh, UK, 1991, pp 80-87.
21. Robertson JIS, Ball SG: Hypertension for the Clinician. WB Saunders, London, 1994.
22. Robertson JIS: Clinical trials in hypertension. In: Clinical Trials in Cardiology. (Eds. Pitt B, Julian D, Pocock S), WB Saunders, London, 1997, pp 115-160.
23. Van Bortel LMAB, De Hoon JNJM, Kool MJF, et al: Pharmacological properties of nebivolol in man. Eur J Clin Pharmacol 1997;51:379-384.
24. Van Bortel LMAB, Schiffers PMH, Mooij JMV: Invasive haemodynamics of nebivolol in hypertensive patients. Drug Invest 1991;3(Suppl 1):60.
25. Van Merode T, Van Bortel LM, Smeets FA, et al: Verapamil and nebivolol improve carotid artery distensibility in hypertensive patients. J Hypertens 1989;7(Suppl): 262-263.